The antimetabolite drug 5-Fluorouracil (5-FU), which is used in first line chemotherapy of CRC [22, 23], targets TYMS by antagonizing dUMP binding on its catalytic domain inhibiting dTMP synthesis (Fig. 5A). Here, TYMS is linked to colorectal carcinoma.